Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring

Clinical Proteomics

Volumn 10, Issue 1, 2013, Pages

  Cerciello, Ferdinando ^a,b   Choi, Meena ^c   Nicastri, Annalisa ^d   Bausch Fluck, Damaris ^a,e   Ziegler, Annemarie ^b,h   Vitek, Olga ^c,f   Felley Bosco, Emanuela ^b   Stahel, Rolf ^b   Aebersold, Ruedi ^a,g   Wollscheid, Bernd ^a,e  

^a Institute of Molecular Systems Biology   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e ETH ZURICH   (Switzerland)

^f Purdue University   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Malignant pleural mesothelioma; Selected reaction monitoring; Serum biomarkers; Surfaceome; Targeted proteomics

Indexed keywords

ANTHRAX TOXIN RECEPTOR 1; ARYLDIALKYLPHOSPHATASE; BASEMENT MEMBRANE SPECIFIC HEPARAN SULFATE PROTEOGLYCAN CORE PROTEIN; CORE PROTEIN; HYPOXIA UPREGULATED PROTEIN 1; INTERCELLULAR ADHESION MOLECULE 1; MESOTHELIN; PEPTIDES AND PROTEINS; RECEPTOR; SERUM PARAOXONASE ARYLESTERASE 1; THROMBOSPONDIN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LUNG NON SMALL CELL CANCER; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCREENING; SELECTED REACTION MONITORING; SENSITIVITY AND SPECIFICITY;

EID: 84901061074     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-10-16     Document Type: Article

References (76)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, et al: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63. discussion 63-55.
2. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451-3457. (Pubitemid 41103650)
3. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW: Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase II trial. J Thorac Oncol 2006, 1:289-295. (Pubitemid 47163979)
4. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, et al: Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202. (Pubitemid 47244366)
5. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, et al: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:3007-3013.
6. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR: Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009, 10:244-248.
7. Sorensen JB, Ravn J, Loft A, Brenoe J, Berthelsen AK: Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008, 34:1090-1096.
8. de Perrot, M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR: Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:1413-1418.
9. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk, N, Winzell P, Hellstrom KE, Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616. (Pubitemid 37443528)
10. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodriguez Portal JA, et al: Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J Clin Oncol 2012, 30:1541-1549.
11. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, et al: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012, 367:1417-1427.
12. Fu Q, Schoenhoff FS, Savage WJ, Zhang P, Van Eyk, JE: Multiplex assays for biomarker research and clinical application: Translational science coming of age. Proteomics Clin Appl 2010, 4:271-284.
13. Picotti P, Bodenmiller B, Aebersold R: Proteomics meets the scientific method. Nat Methods 2013, 10:24-27.
14. Lange V, Picotti P, Domon B, Aebersold R: Selected reaction monitoring for quantitative proteomics: A tutorial. Mol Syst Biol 2008, 4:222.
15. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, et al: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
16. Elschenbroich S, Ignatchenko V, Clarke B, Kalloger S, Boutros P, Gramolini A, Shaw P, Jurisica I, Kislinger T: In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res 2011, 10:2286-2299.
17. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, et al: A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011, 29:625-634.
18. Ziegler A, Cerciello F, Bigosch C, Bausch-Fluck D, Felley-Bosco E, Ossola R, Soltermann A, Stahel RA, Wollscheid B: Proteomic surfaceome analysis of mesothelioma. Lung Cancer 2012, 75:189-196.
19. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
20. Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003, 21:660-666. (Pubitemid 36638093)
21. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H: Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007, 2:334-339. (Pubitemid 47040048)
22. Zhou Y, Aebersold R, Zhang H: Isolation of N-linked glycopeptides from plasma. Anal Chem 2007, 79:5826-5837. (Pubitemid 47229834)
23. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, Domon B: High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007, 6:1809-1817. (Pubitemid 350031682)
24. Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B, Wenschuh H, Aebersold R: High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 2010, 7:43-46.
25. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996, 93:136-140. (Pubitemid 26041483)
26. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KE: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006, 15:1014-1020. (Pubitemid 43823532)
27. Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO: Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006, 15:1751.
28. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY: MESOMARK: A potential test for malignant pleural mesothelioma. Clin Chem 2007, 53:666-672. (Pubitemid 46580236)
29. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999, 96:11531-11536. (Pubitemid 29487415)
30. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 2009, 27:378-386.
31. de Graaf, E, Altelaar, A, van Breukelen, B, Mohammed, S, Heck, A: Improving SRM assay development: A global comparison between triple quadrupole, ion trap, and higher energy CID peptide fragmentation spectra. J Proteome Res 2011, 10:4334-4341.
32. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, et al: A high-confidence human plasma proteome reference set with estimated concentrations in Peptide Atlas. Mol Cell Proteomics 2012, 10:M110 006353.
33. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573. (Pubitemid 41434635)
34. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009, 42:1046-1050.
35. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010, 181:620-625.
36. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P: Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999, 25:25-32. (Pubitemid 29325003)
37. Chang CY, Picotti P, Hüttenhain R, Heinzelmann-Schwarz V, Jovanovic M, Aebersold R, Vitek O: Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol Cell Proteomics 2012, 11:M111 014662.
38. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061. (Pubitemid 32717537)
39. Zhang Z, Chan DW: The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010, 19:2995-2999.
40. Elschenbroich S, Kislinger T: Targeted proteomics by selected reaction monitoring mass spectrometry: Applications to systems biology and biomarker discovery. Mol Biosyst 2011, 7:292-303.
41. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983. (Pubitemid 44215392)
42. Roth J, Zuber C, Park S, Jang I, Lee Y, Kysela K, Fourn VL, Santimaria R, Guhl B, Cho J: Protein N-glycosylation, protein folding, and protein quality control. Mol Cells 2010, 30:497-506.
43. Zhang H, Liu AY, Loriaux P, Wollscheid B, Zhou Y, Watts JD, Aebersold R: Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007, 6:64-71. (Pubitemid 46152692)
44. Fusaro VA, Mani DR, Mesirov JP, Carr SA: Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol 2009, 27:190-198.
45. Duncan MW, Aebersold R, Caprioli RM: The pros and cons of peptidecentric proteomics. Nat Biotechnol 2010, 28:659-664.
46. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P: Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One 2011, 6:e23090.
47. Wang J, Willumsen N, Zheng Q, Xue Y, Karsdal MA, Bay-Jensen AC: Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. Future Oncol 2013, 9:35-44.
48. Craig SE, Brady-Kalnay SM: Cancer cells cut homophilic cell adhesion molecules and run. Cancer Res 2011, 71:303-309.
49. Mason SD, Joyce JA: Proteolytic networks in cancer. Trends Cell Biol 2011, 21:228-237.
50. Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ: Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry 2013, 52:4531-4540.
51. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004, 2:315-326. (Pubitemid 39025294)
52. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L: Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 2012, 53:50-56.
53. Iozzo RV, Sanderson RD: Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011, 15:1013-1031.
54. Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, Croix BS: TEM8 Interacts with the cleaved C5 domain of collagen α3(VI). Cancer Res 2004, 64:817-820. (Pubitemid 38176877)
55. Miyagi T, Hori O, Koshida K, Egawa M, Kato H, Kitagawa Y, Ozawa K, Ogawa S, Namiki M: Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells. Int J Urol 2002, 9:577-585. (Pubitemid 35370731)
56. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD: Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009, 9:182-194.
57. Easton DP, Kaneko Y, Subjeck JR: The Hsp110 and Grp170 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones 2000, 5:276-290.
58. Naaby-Hansen S, Herr JC: Heat shock proteins on the human sperm surface. J Reprod Immunol 2010, 84:32-40.
59. Calvert ME, Digilio LC, Herr JC, Coonrod SA: Oolemmal proteomics - identification of highly abundant heat shock proteins and molecular chaperones in the mature mouse egg and their localization on the plasma membrane. Reprod Biol Endocrinol 2003, 1:27-37.
60. Beachy SH, Kisailus AJ, Repasky EA, Subjeck JR, Wang XY, Kazim AL: Engineering secretable forms of chaperones for immune modulation and vaccine development. Methods 2007, 43:184-193. (Pubitemid 47499073)
61. Altmeyer A, Maki R, Feldweg A, Heike M, Protopopov V, Masur S, Srivastava P: Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int J Cancer 1996, 69:340-349. (Pubitemid 26298302)
62. Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G: The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 2004, 172:972-980. (Pubitemid 38113756)
63. Vega VL, Rodri'guez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, Multhoff G, Arispe N, Maio AD: Hsp70 Translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol 2008, 180:4299-4307.
64. Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, Farrah T, Deutsch EW, Kusebauch U, Moritz RL, et al: Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med 2012, 4:142-194.
65. The SRMAtlas. http://www.srmatlas.org.
66. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009, 64:140-147.
67. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM: Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 2011, 13:961-970.
68. Pedrioli PG, Eng JK, Hubley R, Vogelzang M, Deutsch EW, Raught B, Pratt B, Nilsson E, Angeletti RH, Apweiler R, et al: A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol 2004, 22:1459-1466. (Pubitemid 39482868)
69. Mueller LN, Rinner O, Schmidt A, Letarte S, Bodenmiller B, Brusniak MY, Vitek O, Aebersold R, Müller M: SuperHirn - A novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics 2007, 7:3470-3480. (Pubitemid 47597670)
70. Eng JK, McCormack AL, Yates JR: An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994, 5:976-989.
71. The UniProt Knowledgebase. (UniProtKB) http://www.uniprot.org.
72. Blood Transfusion Service Zürich, SRC, Switzerland. http://www.zhbsd.ch.
73. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ: Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26:966-968.
74. Escher C, Reiter L, Maclean B, Ossola R, Herzog F, Chilton J, Maccoss MJ, Rinner O: Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 2012, 12:1111-1121.
75. Laboratory for Statistical Proteomics and Bioinformatics. http://www.stat.purdue.edu/ovitek/Home.html.
76. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M: pROC: An open-source package for R and S + to analyze and compare ROC curves. BMC Bioinforma 2011, 12:77.